Expert Interview
Discussing the potential of high-dose Spinraza (nusinersen) from Biogen for SMA patients in the DEVOTE and ASCEND studies
Ticker(s): BIIB, NVS, PTCTInstitution: Johns Hopkins University
- Codirector of the Muscular Dystrophy Association Clinic and Professor of Neurology at Johns Hopkins
- Manages 30+ patients with SMA
- Primary research interests involve the basic science and clinical characterization of two important neurologic disorders that affect children: Spinal Muscular Atrophy and Ataxia Telangiectasia. SI on various SMA agents, both investigational and approved
how many SMA patients do you manage?
Added By: wilson_adminHow are you currently deciding between Spinraza, Zolgensma or Evrysdi?
Added By: wilson_adminWhere would high-dose Spinraza fit into the treatment algorithm?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
